Teva CEO Sees Signs Volumes Are Getting Back to Normal

The video discusses the pharmaceutical company's resilience during the COVID-19 pandemic, highlighting their ability to maintain supply chains and launch new products. It addresses the impact of stockpiling on sales, the progress of opioid litigation, and the ongoing DOJ investigation into price fixing. Despite global supply chain challenges, the company has managed to maintain steady operations.

What are the expectations for sales volumes in the upcoming quarters?

What is the company's target for operating margin by 2023?

What is the current status of negotiations regarding the opioid lawsuits?